In this series of 5 blogs, Blog 3 (national and super-provider utilization) was written by Quinn by hand. Here is Blog 3, rewritten from source material entirely by Chat GPT 5.6.
###
88305: Blog 5 of 5 — What Medicare’s Biggest Users Tell Us About the 25-Minute Problem
The developing Medicare controversy over CPT 88305 can be approached from two directions. The Maryland Health Care Commission approached it at the level of the provider-day: multiply the number of 88305 services billed by Medicare’s assigned physician time, and ask whether the resulting workload can fit into an actual day. Sometimes it cannot. Maryland found hundreds of days on which 88305 alone translated into more than 24 hours of nominal physician work.
There is another way to look at the same issue. Instead of studying individual days in Maryland, one can pull back and examine an entire year of national Medicare utilization. CMS’s CY2024 Medicare Physician & Other Practitioners — by Provider and Service public-use file offers exactly that perspective. Filtering the enormous database to a single code, 88305, reveals both the scale of the business and some remarkable concentrations of utilization.
The national data cannot determine how many minutes a pathologist actually spent on a particular slide. Nor should they be treated as if they could. But as a broad reality check on the longstanding assumption that a typical 88305 contains 25 minutes of pathologist intraservice work, they are unusually provocative.
[Note, the following is a huge, confusing and complicated CMS cloud database that AI navigates with ease!]
CMS Medicare Physician & Other Practitioners — by Provider and Service
First, 88305 Is Nearly a Billion-Dollar Medicare Business
In CY2024, 88305 generated roughly $931 million in Medicare allowed amounts. “Allowed” is important terminology here: this is not simply the amount of Medicare checks written to laboratories and physicians, but the Medicare allowed charge, including the beneficiary share where applicable.
The national file contains about 17,430 provider/place-of-service rows for 88305. That does not mean 17,430 different physicians. CMS aggregates this file by NPI, HCPCS code, and place of service, so one NPI can generate more than one row. Nevertheless, the specialty distribution gives a good picture of where the code lives economically. Roughly 13,700 rows are classified as pathology, about 1,700 as dermatology, and about 900 as gastroenterology. Only a few dozen are classified as urology.
The near-absence of urology is historically interesting. Medicare long ago removed routine prostate needle-biopsy pathology from ordinary per-specimen 88305 billing and moved it to the bundled G0416 structure. No longer could 50 prostate needles be billed as 88305x50 (!). As a result, by now ,urology practices are almost absent from the 88305 business line.
The broad national picture is therefore approximately:
| CY2024 measure | Approximate result |
|---|---|
| 88305 Medicare allowed amount | $931 million |
| Provider/place-of-service rows | 17,430 |
| Clinical Laboratory allowed amount | $226 million |
| Other provider categories | $705 million |
| Average 88305 services per beneficiary | about 2.0 |
For laboratories, pathology groups, and investors who own pathology businesses, this is obviously not an academic argument over a dusty RUC number. Even a moderate change in 88305 valuation could move substantial amounts of money.
The Largest Clinical Laboratories
About $226 million, roughly one quarter of national 88305 allowed dollars in this file, appears under the Clinical Laboratory category. The business is also fairly concentrated. The top 15 laboratory rows alone account for approximately 1.2 million 88305 services and $77 million in allowed amounts, roughly one third of the entire Clinical Laboratory portion.
[INSERT TABLE — TOP 15 CLINICAL LABORATORIES]
 |
| click to enlarge |
The largest laboratory row contains nearly 138,000 88305 services in a single year. Several others exceed 100,000. Those figures are impressive, but they are not inherently implausible. A large pathology laboratory may employ or contract with many pathologists, receive specimens from a wide geographic area, and operate a substantial histology production system.
The interesting exercise is to translate those volumes back into the language of physician time used to construct the fee schedule. The accompanying spreadsheet uses a deliberately conservative assumption of roughly 20 minutes per 88305, rather than Medicare’s 25-minute intraservice figure. Even at 20 minutes, the top 15 laboratories collectively represent about 400,000 nominal pathologist hours, or approximately 200 pathologist-years if a full professional year is represented as 2,000 hours.
At the individual laboratory level, this works out to roughly 9 to 23 pathologist-years of nominal 88305 work per entity. For a sufficiently large laboratory, that is at least conceptually possible. It might actually have a dozen or two dozen pathologists supporting the operation. The calculation therefore does not show that anything is wrong with these laboratories. Instead, it demonstrates the enormous professional workforce that Medicare’s historical time assumption says should sit behind their 88305 production.
The data become stranger when the same exercise is applied to provider records identified with individual NPIs.
When an Individual NPI Begins to Look Like a Pathology Department
The top 15 non-laboratory provider rows—almost all classified as pathology, with one dermatologist—reported roughly 537,000 88305 services during CY2024 and about $32 million in allowed amounts.
[INSERT TABLE — TOP 15 PATHOLOGISTS / DERMATOLOGISTS]
 |
| click to enlarge |
The highest-volume row contains 58,180 services for approximately 32,000 Medicare beneficiaries. Even at the reduced 20-minute assumption used in the spreadsheet, those services correspond to about 19,200 nominal hours of pathologist work. That is nearly ten 2,000-hour professional years compressed into one calendar year.
And the top row is not an isolated statistical freak. Other individual-provider rows translate into five, six, seven, or eight nominal pathologist-years. Even at the bottom of the top-15 table, approximately 25,000 services correspond to more than 8,000 nominal hours, or about four full-time professional years. Taken together, these 15 records represent roughly 177,000 nominal hours, approaching 90 full-time pathologist-years.
Nobody should read those calculations literally and conclude that 15 pathologists somehow performed 90 years of labor during 2024. The point is almost the opposite. If legitimate Medicare billing produces utilization volumes that cannot remotely coexist with the time attached to the service, then the time assumption itself becomes a reasonable object of scrutiny.
There is also an important distinction from the large-laboratory table. These are not merely 15 rows labeled as giant corporate clinical laboratories. CMS identifies these high-volume records with individual NPIs. Payment reassignment, practice organization, technical-component billing, and other claims mechanics can complicate what that means operationally, but the basic observation remains striking.
A Claims-Data Caveat, Once
The CMS public-use file is highly aggregated. In particular, this simple analysis cannot fully disentangle professional-component, technical-component, and global 88305 billing, together with the claims reassignment and date-of-service conventions that may lie behind a particular row. A technical-component-only service obviously should not be converted into 20 or 25 minutes of personal pathologist microscope time.
For example, a "Dr Wilson" may be attributed 5000 units of 88305, but 4500 were technical component only and shipped to a different sign-out doctor. Dr Wilson signed out only 500 interpretations, just ten per week. The simple public tables don't distinguish his global, professional, or "only-technical" billing events.
On the other hand, there is another reason the national analysis may actually understate total physician activity: the CMS file covers traditional Medicare fee-for-service, not the provider’s Medicare Advantage, commercial insurance, Medicaid, or other work. And within fee-for-service, we haven't tallied extra special stains of immunohistochems (each +20 minutes) for the super-providers. While the CMS file (used by me here today) is CMS only, the Maryland file had all-payor origins.
Maryland Asked the Same Question One Day at a Time
This national utilization exercise fits remarkably well with the Maryland analysis that triggered CMS’s current review. The Maryland Health Care Commission used its All-Payer Claims Database to examine claims provider by provider and day by day. It multiplied billed services by the physician intraservice time embedded in the Medicare Physician Fee Schedule and asked whether the resulting workday was plausible.
For 88305, the answer was repeatedly troubling. Maryland identified 1,763 provider-days on which 88305 alone represented more than eight hours of nominal intraservice physician time. On 587 days, 88305 by itself represented more than 24 hours. When the other services billed by those providers were added, the extraordinary days averaged roughly 37 hours of nominal fee-schedule time. The Maryland investigators described 88305 as their most extreme outlier.
- [For more about the Maryland analysis, Mesta et al. published June 2026 in Health Affairs - see our Blog #4.].
Maryland appropriately emphasized that these calculations were not accusations of fraud. Medicare does not require a physician to spend exactly the RUC-assigned number of minutes on every service, and efficiency is not improper. The implication is instead directed back at the valuation methodology: if physicians can legitimately produce service volumes that make the assigned time physically impossible, then perhaps the assigned time is not an accurate description of contemporary practice.
The CY2024 Medicare analysis reaches essentially the same issue from the opposite direction. Maryland finds impossible-looking numbers within particular working days. The national data show individual provider NPIs accumulating several professional years’ worth of nominal time over a calendar year.
Multiple Specimens Are Part of the Story
There is another reason 88305 is particularly interesting as a payment unit. It is fundamentally a specimen-based code, and a single patient encounter can appropriately generate more than one separately examined specimen.
Across the national file, the average is approximately two 88305 services per beneficiary. Gastroenterology runs somewhat higher, around 2.6. A small number of gastroenterology provider rows reach roughly five to ten services per beneficiary.
Those figures are not evidence of overuse by themselves. A colonoscopy or upper endoscopy may appropriately produce specimens from several anatomical sites, and a dermatology encounter may likewise produce multiple biopsies. But the numbers illustrate the economic importance of the specimen as the billing unit. Every additional specimen can generate another 88305 payment and, within the fee-schedule model, another complete block of physician time.
Medicare has encountered this “multiples” issue before. Prostate needle biopsy pathology is the clearest precedent. Under the older system, separating many prostate cores could generate numerous units of 88305. CMS ultimately rejected that linear relationship and adopted G0416, paying a single pathology service regardless of how many prostate needle-biopsy specimens were submitted.
That history does not imply that all 88305 pathology should be bundled. It does demonstrate that CMS has previously concluded that incremental specimen count and incremental professional work need not rise in a one-for-one relationship.
What 88305 Actually Represents
A major complication in any revaluation is that 88305 covers an extraordinarily heterogeneous universe of pathology. A straightforward gastrointestinal biopsy, a small skin specimen, and a diagnostically challenging tissue sample can all fall under the same CPT code even though the professional effort required may differ greatly.
That is why a defense of 88305 based on difficult cases is simultaneously correct and incomplete. Some 88305 cases certainly require 25 minutes. Some require considerably longer. The question for Medicare valuation, however, is not whether an 88305 can take 25 minutes. It is whether 25 minutes is a credible representation of the typical physician intraservice work across millions of services.
This distinction matters because the existing number has more historical pedigree than might initially be assumed. The 25-minute figure is not merely an untouched artifact from the original Harvard RBRVS work three decades ago. The 88305 family was reconsidered, pathologists were resurveyed, and the RUC explicitly accepted 25 minutes of intraservice time in 2010 while retaining the existing work RVU.
That makes the current conflict particularly revealing. The fee-schedule system asked physicians how long the work takes and obtained 25 minutes. A later CMS-sponsored Urban Institute pilot observed a median of only about two minutes, although in a small and nonrepresentative sample. Maryland then applied the fee-schedule time to actual claims and found numerous impossible provider-days. Now the national Medicare data show very high-volume individual provider NPIs whose annual service counts translate into multiple full-time professional years under anything close to the historical time assumption.
None of these observations, individually or collectively, proves that the correct answer is two minutes, five minutes, ten minutes, or fifteen minutes. They do make the status quo increasingly difficult to defend simply by pointing back to the earlier survey.
Why the Commercial Community Should Pay Attention (Private Equity)
The obvious audience for the 88305 debate includes pathologists, CAP, CMS, and the AMA RUC. But the economic audience is wider.
Routine surgical pathology has become a meaningful investment sector. Large national laboratories, regional pathology groups, dermatopathology operations, gastrointestinal pathology businesses, and physician-office laboratories have all attracted strategic buyers and private-equity capital. In many of these businesses, 88305 is not peripheral revenue. It is part of the economic foundation.
A substantial change in 88305 professional valuation could therefore affect acquisition models, practice EBITDA, laboratory staffing economics, and the value attributed to high-throughput pathology platforms. The risk would not be distributed evenly. Businesses whose economics depend heavily on enormous volumes of relatively routine 88305 specimens would logically be more exposed to a major reduction than practices whose revenue is diversified across more complex surgical pathology, molecular testing, consultation, and other services.
The policy dispute consequently has a commercial dimension that may be easy to miss when reading a few paragraphs in the Federal Register. CMS has not yet proposed a specific new work RVU for 88305. But once an almost billion-dollar code enters the potentially misvalued-code process because empirical utilization appears inconsistent with its assigned physician time, anyone valuing a pathology business should at least know that the issue exists.
The Larger RUC Question
The significance of 88305 may ultimately extend beyond pathology. The traditional RUC methodology relies substantially on specialty surveys, clinical vignettes, and comparisons with services that already have established relative values. That creates an internally coherent system: one code is judged relative to another, which is judged relative to another.
What the Maryland analysis introduces is an external test. Instead of asking whether 88305 seems appropriately valued relative to some other service, it asks whether all the assigned minutes can coexist within the ordinary limits of a day.
The national CMS utilization data offer another version of the same test. If an individual provider NPI legitimately accumulates 40,000, 50,000, or nearly 60,000 units of a code in one year, what does that imply about the plausibility of the time attached to each unit?
This does not mean claims data should replace professional judgment. Claims files have their own artifacts and can mislead when modifiers, global services, reassignment, or dates are misunderstood. But the choice need not be between physician surveys and administrative data. A more persuasive valuation system could use both: professional judgment to characterize complexity and intensity, and empirical utilization to test whether the resulting assumptions remain compatible with real-world practice.
Bottom Line
CPT 88305 is nearly a billion-dollar annual Medicare service, and a substantial share of that business is concentrated in very high-volume laboratories and provider practices. The top 15 clinical-laboratory rows alone report more than 1.2 million services. The top 15 individual-provider rows report another 537,000.
The public-use data are not precise enough to convert those service counts into literal pathologist working hours. Professional, technical, and global billing distinctions matter. But the discrepancy is large enough that this caveat does not make the underlying question disappear.
Maryland has already shown that Medicare’s 25-minute assumption can generate provider-days longer than 24 hours. The national CY2024 data now show the same tension across an entire year: some individual provider NPIs report enough 88305 services to represent several full professional years of work under anything close to the historical time assumption.
The question facing CMS is therefore not whether pathologists perform important work, or whether some 88305 cases are difficult and time consuming. Both are obvious. The more precise question is whether 25 minutes remains a plausible typical value for the incremental physician work represented by each of the millions of 88305 services Medicare purchases every year.
The answer will matter directly to pathology. But the precedent may matter much more widely. If CMS begins routinely testing RUC-derived physician times against actual clinical throughput, 88305 may be remembered less as an isolated pathology payment dispute than as an early example of a new way Medicare decides whether its own valuation system still describes the medicine being practiced.
